scispace - formally typeset
A

Azza Karrar

Researcher at Inova Health System

Publications -  5
Citations -  37

Azza Karrar is an academic researcher from Inova Health System. The author has contributed to research in topics: Fatty liver & Steatohepatitis. The author has an hindex of 4, co-authored 5 publications receiving 30 citations.

Papers
More filters
Journal ArticleDOI

Fatigue in chronic liver disease: exploring the role of the autonomic nervous system.

TL;DR: Some general aspects of fatigue, its taxonomy, and the findings reported by Dyson et al. are proposed, which contribute to the understanding of fatigue in chronic liver disease by demonstrating an association between sympathetic over-activity, increased cardiac output and primary sclerosing cholangitis.
Journal ArticleDOI

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)

TL;DR: The neurotransmitters and cytokines were found to be independent predictors of MEH scores in multiple regression analysis andCytokine and neurotransmitter changes are associated with mental and emotional health.
Journal ArticleDOI

Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease.

TL;DR: The findings indicate that HLA class I and II gene polymorphism may be associated with susceptibility to NASH, fibrosis and other pathologic features and may be involved in the pathogenesis of NAFLD.
Journal ArticleDOI

Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease

TL;DR: The aim was to assess the role of disease and cell‐specific antibodies, namely anti‐adipocyte antibodies (anti‐AdAb) in patients with NAFLD and non‐alcoholic steatohepatitis (NASH).
Journal ArticleDOI

Serum Amyloid A Is Strongly Associated With Hyperlipidemia in Patients With Non-alcoholic Fatty Liver Disease (NAFLD): 2090

TL;DR: HCC DNA markers can be detected in urine of patients with HCC by short-amplicon, PCR-based assays and in combination with serum AFP, three biomarker urine DNA testing detected at least 30% more HCC in an open-labeled study compared to serum AFP alone.